Hrt Financial LP Ocugen, Inc. Transaction History

Hrt Financial LP

$20.6 Billion
Q3 2025

A detailed history of Hrt Financial LP transactions in Ocugen, Inc. stock. As of the latest transaction made, Hrt Financial LP holds 374,514 shares of OCGN stock, worth $445,671. This represents 0.0% of its overall portfolio holdings.

Number of Shares

374,514

Previous 257,813 45.27%

Holding current value

$445,671

Previous $250,000 144.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$0.92 - $1.66 $107,364 - $193,723	116,701 Added 45.27%	374,514 $610,000
Q2 2025 Aug 14, 2025	BUY	$0.58 - $1.2 $149,531 - $309,375	257,813 New	257,813 $250,000
Q4 2024 Feb 14, 2025	BUY	$0.72 - $1.08 $124,830 - $187,245	173,375 New	173,375 $138,000
Q1 2024 May 13, 2024	BUY	$0.5 - $1.83 $403,250 - $1.48 Million	806,500 New	806,500 $1.32 Million
Q2 2023 Aug 11, 2023	SELL	$0.45 - $0.88 $340,439 - $665,748	-756,532 Reduced 75.07%	251,196 $136,000

Q1 2023 May 12, 2023	BUY	$0.82 - $1.33 $826,336 - $1.34 Million	1,007,728 New	1,007,728 $859,000
Q3 2022 Nov 14, 2022	BUY	$1.75 - $3.1 $547,911 - $970,585	313,092 New	313,092 $557,000
Q1 2022 May 16, 2022	SELL	$2.34 - $4.72 $85,300 - $172,058	-36,453 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.38 - $15.67 $159,664 - $571,218	36,453 New	36,453 $165,000
Q2 2021 Aug 16, 2021	SELL	$5.52 - $15.68 $3.15 Million - $8.95 Million	-570,857 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.66 - $15.81 $928,735 - $8.85 Million	559,479 Added 4917.2%	570,857 $3.88 Million
Q4 2020 Feb 16, 2021	BUY	$0.28 - $2.6 $3,185 - $29,582	11,378 New	11,378 $20,000

Others Institutions Holding OCGN

# of Institutions

108

Shares Held

60.5M

Call Options Held

531K

Put Options Held

433K

View Full List

About Ocugen, Inc.

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $258M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

More about OCGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.

Account